We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer.
- Authors
Karagol, Hakan; Saip, Pinar; Uygun, Kazim; Caloglu, Murat; Eralp, Yesim; Tas, Faruk; Aydiner, Adnan; Topuz, Erkan
- Abstract
<bold>Background: </bold>Activity of tamoxifen as a salvage therapy in patients with advanced epithelial ovarian cancer was evaluated by a number of studies. In this study, we evaluated efficacy of tamoxifen in our patients with platinum-resistant epithelial ovarian carcinoma.<bold>Patients and Methods: </bold>A retrospective analysis was conducted of patients who received tamoxifen at a dose 20 mg twice daily for the treatment of advanced epithelial ovarian cancer.<bold>Results: </bold>Twenty-nine eligible patients were included to the study. There were 1 (3%) complete response, 2 (7%) partial response, 6 (21%) stable disease, and 20 (69%) progressive disease. All patients were progressed after initiation of tamoxifen. Median progression-free survival was 4 mo (95% CI: 2.98-5.02). Disease progression of 19 (65%) patients were shown within the first 6 mo after initiation of tamoxifen. Progression-free survival was between 6 and 12 mo for 7 (24%) patients and > or =12 mo for 3 (10%) patients. The median survival after initiation of tamoxifen was 15 mo (95% CI: 7.2-22.8). No toxicity attributable to tamoxifen was seen in any of the patients. The only independent prognostic factor that had a significant predictive value for progression- free survival was the response to tamoxifen treatment (p = 0.043, hazard ratio: 0.12, 95% CI: 0.01-0.94).<bold>Conclusion: </bold>Considering minimal side effects and ability to cause objective responses, there is a place for tamoxifen in treatment of patients with platinum-resistant ovarian cancer. A phase III trial is required to con- firm the value of the drug in patients presenting these clinical settings.
- Subjects
ANTINEOPLASTIC agents; TAMOXIFEN; ADENOCARCINOMA; CANCER relapse; DRUG resistance in cancer cells; DRUG dosage; DRUG toxicity; EPITHELIAL cell tumors; OVARIAN tumors; PROGNOSIS; SURVIVAL; TUMORS; ENDOMETRIAL tumors; RETROSPECTIVE studies; SALVAGE therapy
- Publication
Medical Oncology, 2007, Vol 24, Issue 1, p39
- ISSN
1357-0560
- Publication type
journal article
- DOI
10.1007/bf02685901